Jonathan DeLiberty, PhD

Jonathan DeLiberty earned his PhD in Pharmacology at the University of North Carolina at Chapel Hill in the laboratories of Kirsten Bryant and Channing Der. His doctoral studies focused on the therapeutic targeting of RAS-driven metabolic dependencies by autophagy inhibition in the context of pancreatic cancer.

Jon is now a Postdoctoral Research Fellow at the Dana-Farber Cancer Institute in the laboratories of Andrew Aguirre and Joseph Mancias. His research focuses on studying the expression of surface proteins of pancreatic cancer cells in the context of RAS inhibition to inform antibody-based therapeutic strategies. Jon hopes that his work will help reveal underlying mechanisms of resistance to targeted therapies to ultimately identify novel targets to improve patients' treatments and outcomes. In his free time, Jon enjoys surfing, volleyball, bouldering, and reading.